Company intelligence / Profile preview
Alphamab Oncology
Suzhou, Jiangsu, Chinaalphamabonc.com ↗
- Ownership
- Public · 9966
- Employees
- ~420
- Development stage
- Commercial
01
Overview
Alphamab Oncology has a robust pipeline with one approved product—Envafolimab/KNO35—the world’s first subcutaneously injectable PD-L1 inhibitor. Three assets are currently in Phase III or pivotal trials. Clinical data for KN046 show favorable safety and promising efficacy across multiple tumor types. JSKN033 has shown encouraging anti-tumor activity and safety profile in early studies
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesbispecific antibodiessingle-domain antibodiesantibody-drug conjugates (ADCs)bispecific ADCs (BADCs)dual-drug conjugates (BADDC)
- Industry
- Biotech
02
Drug pipeline
29 assets28 more assets in the full pipeline.
Request access →03
Partnerships
CSPC Pharmaceutical Group for licensing agreement(s)various academic collaborations for clinical trial sites such as Fudan University Shanghai Cancer Centerinternational trial sites including the US and Australia for certain programs like KN046 and Envafolimab
Beyond the preview
Go deeper on Alphamab Oncology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alphamab Oncology.